12S128: Latest COVID and Rheumatic Disease Therapies: What You Need to Know

Saturday, November 12, 2022

3:00 PM – 4:00 PM Eastern Time

Location: Exhibit Hall A

CE: 1

All of the relevant financial relationships listed for faculty have been mitigated.

Moderator(s)

Leonard Calabrese, DO

Board Certified Rheumatologist and the Head, Section of Clinical Immunology Department of Rheumatic & Immunologic Disease
Cleveland Clinic
Cleveland, OH, United States

Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); Chemocentryx: Consultant (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Jansen: Advisor or Review Panel Member (Ongoing); Novartis: Consultant (Ongoing); UCB: Consultant (Ongoing)

COVID has presented a unique set of challenges for patients with rheumatologic conditions. In addition to concerns for immunosuppression and risk of infection, they have also faced drug shortages associated with use of their medications for treatment of COVID. In this session, presenters will discuss the convergence of rheumatology and infectious diseases in the management of COVID infections.

Learning Objectives:

Review current literature and guidance on pharmacologic management of patients with rheumatologic diseases during the COVID-19 pandemic
Discuss challenges in treating COVID positive patients with rheumatologic diseases
Describe the intersection of rheumatology and infectious diseases in the utilization of DMARDs for treatment of COVID

Presentations:

3:00 PM – 3:20 PM Eastern Time

TBD
Speaker: Rachael Perritt, PharmD – Hospital of the University of Pennsylvania
3:20 PM – 3:40 PM Eastern Time

TBD
Speaker: Stephen Saw, PharmD – Hospital of the University of Pennsylvania
3:40 PM – 4:00 PM Eastern Time

Q&A